Schmallenberg virus (SBV) is an economically important viral disease in ruminants that can cause abortions, stillbirths, and malformations in newborn animals. It is transmitted primarily by Culicoides biting midges. Currently, there is no vaccine or treatment available for SBV. Pharmaceutical companies are investing heavily in research and development of new therapeutics such as antiviral drugs and vaccines to combat the disease.
The global Schmallenberg Virus Treatment Market is estimated to be valued at US$ 110 Mn in 2023 and is expected to exhibit a CAGR of 5.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
The growing research and development of new therapeutics presents a lucrative market opportunity. Several pharmaceutical companies are conducting clinical trials for novel antiviral drugs and vaccines to treat SBV infections. An effective antiviral drug or vaccine against SBV could generate significant returns for the first company to bring such a product to the market. It will help farmers and veterinarians prevent financial losses owing to SBV outbreaks among livestock. The development of reliable prevention and treatment solutions for SBV is expected to drive significant growth in the market over the forecast period.
Porter's Analysis
Threat of new entrants: The threat of new entrants in the Global Schmallenberg virus treatment market size is low as developing effective treatment requires significant investments in R&D. Established market players also enjoy economies of scale.
Bargaining power of buyers: The bargaining power of buyers is moderate. While treatment options are limited currently, buyers can negotiate on price with suppliers.
Bargaining power of suppliers: A few suppliers catering to specialty veterinary and niche markets implies higher bargaining power.
Threat of new substitutes: No substitute treatments currently exist, reducing the threat of substitutes.
Competitive rivalry: Competition in the market is fierce as key players compete to develop safe and effective treatments and vaccines.
SWOT Analysis
Strengths: Established product pipeline and expertise in related animal disease areas.
Weaknesses: Low disease awareness and diagnostic challenges.
Opportunity: Growing livestock industry in developing nations raises demand.
Threats: Stringent regulations for new product approvals. Unpredictable disease outbreaks affect revenues.
Key Takeaways
The global Schmallenberg virus treatment market is expected to witness high growth driven by the expanding livestock industry in developing regions. The global Schmallenberg Virus Treatment Market is estimated to be valued at US$ 110 Mn in 2023 and is expected to exhibit a CAGR of 5.4% over the forecast period 2023 to 2030.
The Asia Pacific region currently dominates the market and is expected to maintain its lead position over the forecast period. Growth will be fuelled by rising meat consumption and increasing livestock herd sizes in China and India. Europe currently accounts for the largest share of the global market due to frequent outbreaks of the Schmallenberg virus in countries with mature dairy industries such as Germany, France, and the Netherlands. However, its market share is anticipated to decline marginally over the next few years.
Key players operating in the Schmallenberg virus treatment market are ABB Ltd, Toshiba International Corporation, Hitachi Ltd, Emerson Electric Company, Robert Bosch GmbH, Panasonic Corporation, Omron Corporation, Honeywell International Inc., Siemens AG, Rockwell Automation, Schneider Electric SE, and Mitsubishi Electric Corporation. Major players are undertaking collaborations to develop a vaccine for the virus given the lack of therapeutic drugs available. They are also investing in R&D to strengthen their product pipelines.
Get More Insights On This Topic: https://www.newswirestats.com/schmallenberg-virus-treatment-market-forecast-outlook-trend-2023-2030/
Sign in to leave a comment.